公司于近日收到股东蓝色经济区产业投资基金（有限合伙）（以下简称"蓝区基 金"）提交的《关于减持金凯（辽宁）生命科技股份有限公司股份计划期间届满暨减 持结果告知函》，截至本报告披露日，前述股东本次减持计划期限届满。现将有关情 况公告如下： 一、股东减持情况 证券代码：301509 证券简称：金凯生科 公告编号：2025-032 金凯（辽宁）生命科技股份有限公司 关于股东减持股份计划期间届满暨减持结果的公告 股东蓝色经济区产业投资基金（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1、减持股份来源：首次公开发行前持有的公司股份（含该等股份上市后资本公 积金转增股本取得的股份）。 | 股东名称 | 减持方式 | 减持期间 | 减持均价 （元/股） | 减持股数 （股） | 减持比例 （%） | | --- | --- | --- | --- | --- | --- | | | | 2025年7月11日至 | | | | | 蓝区基金 | 集中竞价方式 | 2025年9月1日 | 41.64 | 760 ...

来源：新浪证券-红岸工作室 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 9月4日，金凯生科跌0.28%，成交额1.70亿元，换手率7.65%，总市值46.60亿元。 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额5719.33万，占总 ...

持续督导的培训报告 通过线上方式进行培训。 关于对金凯（辽宁）生命科技股份有限公司 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相 关法律法规的要求，中信建投证券股份有限公司（以下简称"中信建投"、"保 荐人"）作为金凯（辽宁）生命科技股份有限公司（以下简称"金凯生科"或"公 司"）首次公开发行股票并在创业板上市的保荐人及持续督导机构，项目组成员 于 2025 年 8 月 28 日对公司到场的董事、监事、高级管理人员、中层以上管理人 员及公司控股股东和实际控制人等相关人员进行了专门培训，并对未到场的相关 人员派发了相关培训资料，督促其认真学习培训内容，本次培训的具体情况如下： 中信建投证券股份有限公司 一、培训时间 2025 年 8 月 28 日 二、培训地点 逯金才 张林 中信建投证券股份有限公司 年 月 日 2 三、培训内容 本次培训内容为创业板上市公司资本运作、规范运作、募集资金使用与管理 规范等，本次培训结合法律法规及相关案例，从创业板上市公司资本运作、规范 运作、募集资金使用等方面进行了讲解。通过本次培训，公司董事、监事、高级 管理人员、中层以上管理人员及公 ...

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., specializes in providing custom research and development services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and custom R&D production services for new drug development projects [2][8]. - The company has launched projects for pharmaceutical intermediates, including the production of Semaglutide oral formulation absorption enhancers [2][3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the first half of 2025, the company achieved revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On August 28, the company's stock price fell by 1.21%, with a trading volume of 225 million yuan and a turnover rate of 9.93%, resulting in a total market capitalization of 4.83 billion yuan [1]. - The stock has seen a net outflow of 12.15 million yuan from major investors today, with a continuous reduction in major funds over the past three days [5][6]. Group 4: Technical Analysis - The average trading cost of the stock is 42.20 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [7]. - The current stock price is near a support level of 40.00 yuan, which is critical for potential rebound or further decline [7].

Group 1 - The stock price of Jinkai Biotechnology is reported at 42.65 yuan, down 1.15 yuan or 2.63% from the previous trading day, with a trading volume of 3.01 billion yuan and a turnover rate of 12.27% [1] - Jinkai Biotechnology is a global small molecule CDMO service provider focused on custom R&D production services for innovative drug manufacturers, covering process development, optimization, and large-scale production [1] - The company operates in sectors including bioproducts, CRO, and weight loss drugs [1] Group 2 - The semi-annual report disclosed on August 23 shows that the company achieved revenue of 348 million yuan in the first half of the year, a year-on-year increase of 32.98% [1] - The net profit attributable to the parent company reached 71.76 million yuan, representing a year-on-year growth of 123.61% [1] - The net profit excluding non-recurring gains and losses was 59.17 million yuan, up 141.51% year-on-year, with a net cash flow from operating activities of 74.72 million yuan, an increase of 14.47% [1] Group 3 - Today, the net outflow of main funds was 19.71 million yuan, accounting for 0.81% of the circulating market value; over the past five days, the cumulative net outflow of main funds was 709,500 yuan, representing 0.03% of the circulating market value [1]

来源：新浪证券-红岸工作室 8月26日，金凯生科跌2.63%，成交额3.01亿元，换手率12.27%，总市值51.37亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资料显示，金凯(辽宁)生命科技股份有限公司位于辽宁省阜新市阜蒙县伊吗图 ...

Core Insights - The Chinese biopharmaceutical industry is experiencing a surge in performance, with 69.23% of 39 innovative drug companies reporting positive net profit growth in their semi-annual reports [1] - Six companies reported over 100% year-on-year growth in net profit, indicating strong development momentum in the sector [1] Company Performance - **Kexing Pharmaceutical** achieved the highest net profit growth at 576.45%, totaling 0.80 billion yuan, focusing on antiviral, oncology, and immunology treatments [1] - **Sanno Bio** reported a 308.29% increase in net profit, reaching 0.89 billion yuan, driven by significant growth in raw material drug sales [2][3] - **Jinkai Biotechnology** saw a 123.61% increase in net profit, providing custom development services for small molecule drugs [3] - **Wuxi AppTec** and **Hengrui Medicine** also ranked among the top three companies by revenue, with 207.99 billion yuan and 157.61 billion yuan respectively [4] Industry Trends - The industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion stage [4] - Recent policy measures from the National Healthcare Security Administration aim to support high-quality development in innovative drug research and market application [4] - Analysts predict that the innovative drug sector will continue to thrive, driven by efficiency and cost advantages in drug development [5]

Meeting Overview - The second meeting of the Supervisory Board of Jinkai (Liaoning) Life Science Co., Ltd. was held on August 22, 2025, with all three supervisors present, ensuring a valid meeting [1][2] Financial Reporting - The Supervisory Board reviewed and confirmed that the company's 2025 semi-annual report and its summary were prepared in accordance with relevant laws and regulations, accurately reflecting the company's financial status and operational results without any false records or omissions [1][2] Fund Management - The company adhered to the regulations regarding the management and use of raised funds, confirming that there were no violations in the storage and management of these funds [2][3] - The proposal to change the method of fund allocation from "loaning to subsidiaries" to "capital increase in subsidiaries" was deemed reasonable and beneficial for improving fund utilization efficiency and protecting shareholder interests [2][3] Cash Management - The use of part of the idle raised funds and self-owned funds for cash management was approved, ensuring it would not affect the investment projects or normal operations of the company [3][4] Capital Supplementation - The proposal to use part of the raised excess funds for permanent working capital supplementation was found to comply with regulations and not conflict with the investment plans [4] Corporate Governance - The revision of the company's articles of association was approved, aimed at optimizing governance and protecting the rights of investors, especially minority shareholders [4][5] Subsidiary Investment - The decision to use self-owned funds to increase capital in Kingchem Life Science LLC for the construction of Kingchem Laboratories Inc. was supported, aligning with the company's strategy to enhance international competitiveness and support global customer needs [5]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：301509 证券简称：金凯生科 公告编号：2025-030 金凯（辽宁）生命科技股份有限公司 金凯（辽宁）生命科技股份有限公司（以下简称"金凯生科"或"公司"）于 年第一次临时股东会的议案》。根据《中华人民共和国公司法》的相关规定，金凯 生科 2025 年第一次临时股东会拟于 2025 年 9 月 22 日（星期一）下午 14 时在金凯 （辽宁）生命科技股份有限公司会议室以现场表决与网络投票相结合的方式召开， 审议本会议通知所列议案。现将相关事项通知如下： 一、召开会议的基本情况 部门规章、规范性文件和《公司章程》的规定。 （1）会议召开的时间：2025 年 9 月 22 日（星期一）下午 14 时。 （2）网络投票时间： 其中，通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 22 日 上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。通过深圳证券交易所互联网系 统投票的具体时间为 2025 年 9 月 22 日上午 9:15 至下午 15:00 的任 ...

| 金凯（辽宁）生命科技股份有限公司 | 2025 年半年度报告摘 | | | --- | --- | --- | | 要 | | | | 证券代码：301509 证券简称：金凯生科 | 公告编号：2025- | | | 020 | | | | 金凯（辽宁）生命科技股份有限公司 | | | | 一、重要提示 | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | 资者应当到证监 | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | 非标准审计意见提示 | | | | □适用 ?不适用 | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | □适用 ?不适用 | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | □适用 ?不适用 | | | | 二、公司基本情况 | | | | 股票简称 金凯生科 股票代码 | 301509 | | | 股票上市交易所 ...